Werner syndrome is an autosomal recessive genetic disorder of adult-onset premature aging caused by biallelic pathogenic variants in the WRN gene. This gene encodes a protein with helicase and exonuclease activity involved in DNA replication, repair, and maintenance. Its alteration causes genomic instability, accelerated cellular senescence, and early onset of age-associated manifestations, along with predisposition to tumors.
Werner syndrome
The WRN gene provides instructions for making the WRN protein, a RecQ helicase/exonuclease. This protein participates in processes essential for genome stability, such as DNA replication, break repair, recombination, and telomere maintenance. Under normal conditions, WRN helps cells accurately copy and repair their genetic material, especially when damage or blockages occur during replication.
When pathogenic variants exist in both copies of WRN, the protein can be truncated, unstable, or unable to localize correctly to the nucleus, compromising its repair function. The accumulation of DNA damage promotes chromosomal instability, telomere shortening, and premature cell senescence. Clinically, affected individuals typically have seemingly normal childhood development but fail to experience the expected pubertal growth spurt and begin to develop signs of accelerated aging in late adolescence or early adulthood. The disease is very rare, with an estimated global prevalence of about 1 in 1,000,000 people, although it is more common in Japan and Sardinia due to founder effects.
Symptoms
Symptoms typically appear between late adolescence and young adulthood. Initial signs include absence of pubertal growth spurt, relative short stature, premature graying and hair loss, hoarse voice, and skin changes similar to scleroderma, with thin, tight, or atrophic skin.
Later on, bilateral cataracts, chronic skin ulcers, type 2 diabetes mellitus, osteoporosis, hypogonadism, early atherosclerosis, and soft tissue calcifications are common. There is also an increased risk of neoplasms, especially sarcomas, melanoma, thyroid cancer, and other tumors. The progression is progressive, and mortality is mainly related to cardiovascular complications and cancer.
Disease management
There is no curative treatment for Werner syndrome, so management focuses on monitoring and early treatment of complications. Multidisciplinary follow-up is recommended with ophthalmological monitoring for cataracts, dermatological evaluation of ulcers and skin lesions, metabolic control of diabetes and dyslipidemia, cardiovascular prevention, osteoporosis study, and periodic oncological surveillance.
It is also important to avoid factors that can increase vascular or skin damage, such as tobacco and excessive sun exposure. Genetic counseling allows for the identification of carriers in the family and estimation of reproductive risk.
Genes analyzed
Bibliography
Oshima J, Martin GM, Hisama FM. Werner Syndrome. 2002 Dec 2 [updated 2021 May 13]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Oshima J, Sidorova JM, Monnat RJ Jr. Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev. 2017 Jan;33:105-114.
Mukherjee S, Sinha D, Bhattacharya S, et al. Werner Syndrome Protein and DNA Replication. Int J Mol Sci. 2018 Nov 2;19(11):3442.
Paccosi E, Guzzon D, Proietti-De-Santis L. Genetic and Epigenetic Insights into Werner Syndrome. Cytogenet Genome Res. 2025 Feb 14:1-15.
